OBJECTIVE: To examine in patients treated with a regimen including single-pill combinations (SPCs) of amlodipine/valsartan (1) blood pressure (BP) reduction and control, total cardiovascular risk ...

53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...

The 15 medicines included in the initiative include three branded medicines: valsartan ... from Novartis' Sandoz unit that are used to treat heart failure and hypertension (amlodipine, bisoprolol ...